No funding was provided for this manuscript.
Conflicts of interest/Competing interests
The opinions expressed in this article are those of the authors alone and do not reflect opinions of their employers. Furthermore, the authors have no financial, academic, or research interests in the topics discussed within this article and have fully disclosed their personal financial conflicts and their volunteer work with the Reagan-Udall Foundation. Matthew Roe: Employee of and holds stock options in Verana Health, honoraria for serving on a clinical endpoint adjudication committee for Novo Nordisk, honoraria for serving on independent data monitoring committees for Regeneron and Roche-Genetech and serves on the Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection Steering Committee of the Reagan-Udall Foundation for the FDA. Bray Patrick-Lake: Employee of and holds stock options in Evidation Health, honoraria for consulting with Bayer, and serves on the Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection Steering Committee of the Reagan-Udall Foundation for the FDA. Andrew von Eschenbach: President, Samaritan Health Initiatives, Inc., Senior Fellow, Milken Institute, Senior Fellow and Member of Advisory Committee on Medical Innovation, Bipartisan Policy Center, and member of International Advisory Council, Chugai Pharmaceuticals.
Consent to participate
Consent for publication
All authors approve of the final version of this manuscript and give consent for publication.
Availability of data and material
All authors contributed to the drafting and review of this article.